Publication

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment

Lamberts, T. E., Menke-van der Houven van Oordt, C. W., Ter Weele, E. J., Bensch, F., Smeenk, M. M., Voortman, J., Hoekstra, O. S., Williams, S. P., Fine, B. M., Maslyar, D., de Jong, J. R., Gietema, J. A., Schröder, C. P., Bongaerts, A. H. H., Lub-de Hooge, M. N., Verheul, H. M. W., Sanabria Bohorquez, S., Glaudemans, A. W. J. M. & de Vries, E. G., 20-Nov-2015, In : Clinical Cancer Research. 22, 7, p. 1642-1652 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Lamberts, T. E., Menke-van der Houven van Oordt, C. W., Ter Weele, E. J., Bensch, F., Smeenk, M. M., Voortman, J., ... de Vries, E. G. (2015). ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. Clinical Cancer Research, 22(7), 1642-1652. https://doi.org/10.1158/1078-0432.CCR-15-1272

Author

Lamberts, Titia E ; Menke-van der Houven van Oordt, Catharina W ; Ter Weele, Eva J ; Bensch, Frederike ; Smeenk, Michiel M ; Voortman, Johannes ; Hoekstra, Otto S ; Williams, Simon P ; Fine, Bernard M ; Maslyar, Daniel ; de Jong, Johan R. ; Gietema, Jourik A ; Schröder, Carolina P ; Bongaerts, Alfons H H ; Lub-de Hooge, Marjolijn N ; Verheul, Henk M W ; Sanabria Bohorquez, Sandra ; Glaudemans, Andor W J M ; de Vries, Elisabeth G. / ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. In: Clinical Cancer Research. 2015 ; Vol. 22, No. 7. pp. 1642-1652.

Harvard

Lamberts, TE, Menke-van der Houven van Oordt, CW, Ter Weele, EJ, Bensch, F, Smeenk, MM, Voortman, J, Hoekstra, OS, Williams, SP, Fine, BM, Maslyar, D, de Jong, JR, Gietema, JA, Schröder, CP, Bongaerts, AHH, Lub-de Hooge, MN, Verheul, HMW, Sanabria Bohorquez, S, Glaudemans, AWJM & de Vries, EG 2015, 'ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment', Clinical Cancer Research, vol. 22, no. 7, pp. 1642-1652. https://doi.org/10.1158/1078-0432.CCR-15-1272

Standard

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. / Lamberts, Titia E; Menke-van der Houven van Oordt, Catharina W; Ter Weele, Eva J; Bensch, Frederike; Smeenk, Michiel M; Voortman, Johannes; Hoekstra, Otto S; Williams, Simon P; Fine, Bernard M; Maslyar, Daniel; de Jong, Johan R.; Gietema, Jourik A; Schröder, Carolina P; Bongaerts, Alfons H H; Lub-de Hooge, Marjolijn N; Verheul, Henk M W; Sanabria Bohorquez, Sandra; Glaudemans, Andor W J M; de Vries, Elisabeth G.

In: Clinical Cancer Research, Vol. 22, No. 7, 20.11.2015, p. 1642-1652.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Lamberts TE, Menke-van der Houven van Oordt CW, Ter Weele EJ, Bensch F, Smeenk MM, Voortman J et al. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. Clinical Cancer Research. 2015 Nov 20;22(7):1642-1652. https://doi.org/10.1158/1078-0432.CCR-15-1272


BibTeX

@article{72220ef0dfd84086b656cf16adf56b4d,
title = "ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment",
abstract = "PURPOSE: Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers, making it a potential drug target. We performed an 89Zr-PET imaging study with MMOT0530A, a MSLN antibody, in conjunction with a phase I study with the antibody-drug conjugate DMOT4039A, containing MMOT0530A bound to MMAE. The aim was to study antibody tumor uptake, whole body distribution and relation between uptake, response to treatment and MSLN expression.EXPERIMENTAL DESIGN: Before DMOT4039A treatment, patients received 37 MBq 89Zr-MMOT0530A followed by PET/CT imaging 2, 4, and 7 days post injection (pi). Tracer uptake was expressed as standardized uptake value (SUV). MSLN expression was determined with immunohistochemistry (IHC) on archival tumor tissue.RESULTS: Eleven patients were included, seven with pancreatic and four with ovarian cancer. IHC MSLN expression varied from absent to strong. Suitable tracer antibody dose was 10 mg MMOT0530A and optimal imaging time was 4 and 7 days pi. Tumor tracer uptake occurred in 37 lesions with mean SUVmax of 13.1 (± 7.5) on PET 4 days pi, with 11.5 (± 7.5) in (N=17) pancreatic and 14.5 (± 8.7) in (N=20) ovarian cancer lesions. Within patients, a mean 2.4-fold (± 1.10) difference in uptake between tumor lesions existed. Uptake in blood, liver, kidneys, spleen and intestine reflected normal antibody distribution. Tracer tumor uptake was correlated to immunohistochemistry. Best response to DMOT4039A was partial response in one patient.CONCLUSIONS: With 89Zr-MMOT0530A-PET pancreatic and ovarian cancer lesions as well as antibody biodistribution could be visualized. This technique can potentially guide individualized antibody-based treatment.",
author = "Lamberts, {Titia E} and {Menke-van der Houven van Oordt}, {Catharina W} and {Ter Weele}, {Eva J} and Frederike Bensch and Smeenk, {Michiel M} and Johannes Voortman and Hoekstra, {Otto S} and Williams, {Simon P} and Fine, {Bernard M} and Daniel Maslyar and {de Jong}, {Johan R.} and Gietema, {Jourik A} and Schr{\"o}der, {Carolina P} and Bongaerts, {Alfons H H} and {Lub-de Hooge}, {Marjolijn N} and Verheul, {Henk M W} and {Sanabria Bohorquez}, Sandra and Glaudemans, {Andor W J M} and {de Vries}, {Elisabeth G}",
note = "Copyright {\circledC} 2015, American Association for Cancer Research.",
year = "2015",
month = "11",
day = "20",
doi = "10.1158/1078-0432.CCR-15-1272",
language = "English",
volume = "22",
pages = "1642--1652",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "AMER ASSOC CANCER RESEARCH",
number = "7",

}

RIS

TY - JOUR

T1 - ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment

AU - Lamberts, Titia E

AU - Menke-van der Houven van Oordt, Catharina W

AU - Ter Weele, Eva J

AU - Bensch, Frederike

AU - Smeenk, Michiel M

AU - Voortman, Johannes

AU - Hoekstra, Otto S

AU - Williams, Simon P

AU - Fine, Bernard M

AU - Maslyar, Daniel

AU - de Jong, Johan R.

AU - Gietema, Jourik A

AU - Schröder, Carolina P

AU - Bongaerts, Alfons H H

AU - Lub-de Hooge, Marjolijn N

AU - Verheul, Henk M W

AU - Sanabria Bohorquez, Sandra

AU - Glaudemans, Andor W J M

AU - de Vries, Elisabeth G

N1 - Copyright © 2015, American Association for Cancer Research.

PY - 2015/11/20

Y1 - 2015/11/20

N2 - PURPOSE: Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers, making it a potential drug target. We performed an 89Zr-PET imaging study with MMOT0530A, a MSLN antibody, in conjunction with a phase I study with the antibody-drug conjugate DMOT4039A, containing MMOT0530A bound to MMAE. The aim was to study antibody tumor uptake, whole body distribution and relation between uptake, response to treatment and MSLN expression.EXPERIMENTAL DESIGN: Before DMOT4039A treatment, patients received 37 MBq 89Zr-MMOT0530A followed by PET/CT imaging 2, 4, and 7 days post injection (pi). Tracer uptake was expressed as standardized uptake value (SUV). MSLN expression was determined with immunohistochemistry (IHC) on archival tumor tissue.RESULTS: Eleven patients were included, seven with pancreatic and four with ovarian cancer. IHC MSLN expression varied from absent to strong. Suitable tracer antibody dose was 10 mg MMOT0530A and optimal imaging time was 4 and 7 days pi. Tumor tracer uptake occurred in 37 lesions with mean SUVmax of 13.1 (± 7.5) on PET 4 days pi, with 11.5 (± 7.5) in (N=17) pancreatic and 14.5 (± 8.7) in (N=20) ovarian cancer lesions. Within patients, a mean 2.4-fold (± 1.10) difference in uptake between tumor lesions existed. Uptake in blood, liver, kidneys, spleen and intestine reflected normal antibody distribution. Tracer tumor uptake was correlated to immunohistochemistry. Best response to DMOT4039A was partial response in one patient.CONCLUSIONS: With 89Zr-MMOT0530A-PET pancreatic and ovarian cancer lesions as well as antibody biodistribution could be visualized. This technique can potentially guide individualized antibody-based treatment.

AB - PURPOSE: Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers, making it a potential drug target. We performed an 89Zr-PET imaging study with MMOT0530A, a MSLN antibody, in conjunction with a phase I study with the antibody-drug conjugate DMOT4039A, containing MMOT0530A bound to MMAE. The aim was to study antibody tumor uptake, whole body distribution and relation between uptake, response to treatment and MSLN expression.EXPERIMENTAL DESIGN: Before DMOT4039A treatment, patients received 37 MBq 89Zr-MMOT0530A followed by PET/CT imaging 2, 4, and 7 days post injection (pi). Tracer uptake was expressed as standardized uptake value (SUV). MSLN expression was determined with immunohistochemistry (IHC) on archival tumor tissue.RESULTS: Eleven patients were included, seven with pancreatic and four with ovarian cancer. IHC MSLN expression varied from absent to strong. Suitable tracer antibody dose was 10 mg MMOT0530A and optimal imaging time was 4 and 7 days pi. Tumor tracer uptake occurred in 37 lesions with mean SUVmax of 13.1 (± 7.5) on PET 4 days pi, with 11.5 (± 7.5) in (N=17) pancreatic and 14.5 (± 8.7) in (N=20) ovarian cancer lesions. Within patients, a mean 2.4-fold (± 1.10) difference in uptake between tumor lesions existed. Uptake in blood, liver, kidneys, spleen and intestine reflected normal antibody distribution. Tracer tumor uptake was correlated to immunohistochemistry. Best response to DMOT4039A was partial response in one patient.CONCLUSIONS: With 89Zr-MMOT0530A-PET pancreatic and ovarian cancer lesions as well as antibody biodistribution could be visualized. This technique can potentially guide individualized antibody-based treatment.

U2 - 10.1158/1078-0432.CCR-15-1272

DO - 10.1158/1078-0432.CCR-15-1272

M3 - Article

C2 - 26589435

VL - 22

SP - 1642

EP - 1652

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -

ID: 26353775